Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/30892
Title: Acute heart failure
Authors: Arrigo, Mattia
Jessup, Mariell
MULLENS, Wilfried 
Reza, Nosheen
Shah, Ajay M.
Sliwa, Karen
Mebazaa, Alexandre
Issue Date: 2020
Publisher: NATURE PUBLISHING GROUP
Source: Nature Reviews Disease Primers, 6 (1) (Art N° 16)
Abstract: Acute heart failure (AHF) is a syndrome characterized by signs and symptoms of heart failure (typically systemic congestion) that occurs in the presence of an underlying cardiac dysfunction (previously diagnosed, undiagnosed or new-onset) and precipitating factors. AHF is associated with high mortality and hospital readmission rates. Acute heart failure (AHF) is a syndrome defined as the new onset (de novo heart failure (HF)) or worsening (acutely decompensated heart failure (ADHF)) of symptoms and signs of HF, mostly related to systemic congestion. In the presence of an underlying structural or functional cardiac dysfunction (whether chronic in ADHF or undiagnosed in de novo HF), one or more precipitating factors can induce AHF, although sometimes de novo HF can result directly from the onset of a new cardiac dysfunction, most frequently an acute coronary syndrome. Despite leading to similar clinical presentations, the underlying cardiac disease and precipitating factors may vary greatly and, therefore, the pathophysiology of AHF is highly heterogeneous. Left ventricular diastolic or systolic dysfunction results in increased preload and afterload, which in turn lead to pulmonary congestion. Fluid retention and redistribution result in systemic congestion, eventually causing organ dysfunction due to hypoperfusion. Current treatment of AHF is mostly symptomatic, centred on decongestive drugs, at best tailored according to the initial haemodynamic status with little regard to the underlying pathophysiological particularities. As a consequence, AHF is still associated with high mortality and hospital readmission rates. There is an unmet need for increased individualization of in-hospital management, including treatments targeting the causative factors, and continuation of treatment after hospital discharge to improve long-term outcomes.
Notes: Mebazaa, A (reprint author), Univ Paris, INSERM, MASCOT, Paris, France.; Mebazaa, A (reprint author), Hop Lariboisiere, AP HP, Dept Anesthesia Burn & Crit Care Med, Paris, France.
alexandre.mebazaa@aphp.fr
Other: Mebazaa, A, (reprint author), Univ Parirs, INSERM, MASCOT, Paris, France; Hop Lariboisiere, AP HP, Dept Anesthesia Burn & Crit Care Med, Paris, France. alexandre.mebazaa@aphp.fr
Keywords: In-Hospital Mortality;Acute Myocardial-Infarction;Reduced Ejection Fraction;2013 Accf/Aha Guideline;Natriuretic Peptide;European-Society;Precipitating Factors;Pulmonary Congestion;Volume Expansion;Lung Ultrasound
Document URI: http://hdl.handle.net/1942/30892
ISSN: 2056-676X
e-ISSN: 2056-676X
DOI: 10.1038/s41572-020-0151-7
ISI #: WOS:000519016800001
Rights: Springer Nature Limited 2020
Category: A1
Type: Journal Contribution
Validations: ecoom 2021
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
arrigo.pdfPublished version1.63 MBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

1
checked on Sep 5, 2020

WEB OF SCIENCETM
Citations

227
checked on Apr 30, 2024

Page view(s)

26
checked on Jun 15, 2022

Download(s)

6
checked on Jun 15, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.